203 related articles for article (PubMed ID: 37803456)
1. Anakinra and hepatotoxicity in pediatric rheumatology: a case series.
Martins FR; Azevedo AC; Ganhão S; Aguiar F; Rodrigues M; Brito I
Pediatr Rheumatol Online J; 2023 Oct; 21(1):112. PubMed ID: 37803456
[TBL] [Abstract][Full Text] [Related]
2. A case of incomplete Kawasaki disease with extremely high serum ferritin and interleukin-18 levels.
Noto T; Seto H; Fukuhara J; Murabayashi M; Yachie A; Ayusawa M; Morioka I
BMC Pediatr; 2018 Dec; 18(1):386. PubMed ID: 30541507
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
[TBL] [Abstract][Full Text] [Related]
4. Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
Huang S; Liu Y; Yan W; Zhang T; Wang P; Zhu M; Zhang X; Zhou P; Fan Z; Yu H
Pediatr Rheumatol Online J; 2024 May; 22(1):58. PubMed ID: 38783316
[TBL] [Abstract][Full Text] [Related]
5. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
Sönmez HE; Demir S; Bilginer Y; Özen S
Clin Rheumatol; 2018 Dec; 37(12):3329-3335. PubMed ID: 29663156
[TBL] [Abstract][Full Text] [Related]
6. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
7. Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Gorelik M; Fall N; Altaye M; Barnes MG; Thompson SD; Grom AA; Hirsch R
J Rheumatol; 2013 Jul; 40(7):1191-9. PubMed ID: 23678162
[TBL] [Abstract][Full Text] [Related]
8. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
9. Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.
Otar Yener G; Paç Kısaarslan A; Ulu K; Atalay E; Haşlak F; Özdel S; Bozkaya Yücel B; Gezgin Yıldırım D; Çakmak F; Öztürk K; Çakan M; Balık Z; Hasbal Akkuş C; Yıldız M; Erat T; Çetin BŞ; Yılmaz M; Bağlan E; Laçinel Gürlevik S; Atasayan V; Karadağ ŞG; Adrovic A; Çağlayan Ş; Tanatar A; Demirkan FG; Coşkuner T; Akgün Ö; Kasap Cüceoğlu M; Kavrul Kayaalp G; Şahin S; Başaran Ö; Demir F; Barut K; Çiftel M; Gürses D; Baykan A; Özsürekçi Y; Karagöz T; Sönmez HE; Bilginer Y; Aktay Ayaz N; Aydoğ Ö; Yüksel S; Sözeri B; Kasapçopur Ö; Özen S
Rheumatol Int; 2022 May; 42(5):879-889. PubMed ID: 34491393
[TBL] [Abstract][Full Text] [Related]
10. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases.
Lin CI; Yu HH; Lee JH; Wang LC; Lin YT; Yang YH; Chiang BL
Clin Rheumatol; 2012 Aug; 31(8):1223-30. PubMed ID: 22615046
[TBL] [Abstract][Full Text] [Related]
11. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
12. Is it possible to predict a disease course prone to macrophage activation syndrome at systemic juvenile idiopathic arthritis diagnosis?
Batu ED; Sener S; Balık Z; Bayındır Y; Cam V; Kasap Cuceoglu M; Uysal O; Aliyev E; Basaran Ö; Bilginer Y; Özen S
Clin Rheumatol; 2024 Jan; 43(1):415-421. PubMed ID: 38012469
[TBL] [Abstract][Full Text] [Related]
13. Occult macrophage activation syndrome in systemic-onset juvenile idiopathic arthritic syndrome--a case report.
Zeng P; Li F; Zeng H
Acta Reumatol Port; 2013; 38(3):196-200. PubMed ID: 24149017
[TBL] [Abstract][Full Text] [Related]
14. A rare case of coronary artery complication in a child with systemic juvenile idiopathic arthritis and macrophage activation syndrome: case report and literature review.
Zhang L; Wei Y; Zeng N; Wang L; Chen X; Yang J; Xiao X
Pediatr Rheumatol Online J; 2024 Jan; 22(1):4. PubMed ID: 38166957
[TBL] [Abstract][Full Text] [Related]
15. Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review.
Aguiar CL; Pan N; Adams A; Barinstein L; Lehman TJ
Clin Rheumatol; 2015 Oct; 34(10):1821-4. PubMed ID: 25697878
[TBL] [Abstract][Full Text] [Related]
16. Macrophage Activation Syndrome.
Sen ES; Clarke SL; Ramanan AV
Indian J Pediatr; 2016 Mar; 83(3):248-53. PubMed ID: 26400031
[TBL] [Abstract][Full Text] [Related]
17. Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.
Wagner-Weiner L
Pediatr Ann; 2015 Jun; 44(6):e142-7. PubMed ID: 26114369
[TBL] [Abstract][Full Text] [Related]
18. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
[TBL] [Abstract][Full Text] [Related]
19. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
[TBL] [Abstract][Full Text] [Related]
20. Severe hepatotoxicity as a rare side effect of anakinra in a patient with systemic JIA.
Murray GM; Ng SK; Beasley D; Johansen L; Ramanan AV
Rheumatology (Oxford); 2021 Sep; 60(9):e307-e308. PubMed ID: 34469571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
